Evidence map›Paper›PMID 38068476›Full record

ArticleJournal of clinical medicine2023

What We Should Expect from an Innovative Intra-Articular Hyaluronic Acid Product: Expert Opinion Based on a Comprehensive Review of the Literature.

Alberto Migliore, Emmanuel Maheu, Luca Saccone, Gustavo C de Campos, Lyudmila Alekseeva, Xavier Chevalier, Thierry Conrozier, Sergio Crimaldi, Demirhan Diracoglu, Gabriel Herrero-Beaumont and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Intra-articular hyaluronic acid injections for hip osteoarthritis: a level I systematic review.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 19 institutions in 13 countries.

Alberto MiglioreRheumatology Unit, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy.
Emmanuel MaheuRheumatology Department, AP-HP, Saint-Antoine Hospital, 75012 Paris, France.ORCID 0000-0001-6615-3630
Luca SacconeDepartment of Orthopaedics and Traumatology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy.ORCID 0000-0001-8660-3213
Gustavo C de CamposDepartment of Orthopaedics and Traumatology, University of Campinas, Saint Paul 13083, Brazil.
Lyudmila AlekseevaDepartment of Metabolic Diseases of Bone and Joints, VA Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.
Xavier ChevalierDepartment of Rheumatology, Hôpital Henri-Mondor, Université UPEC Paris XII, 94000 Paris, France.
Thierry ConrozierService de Rhumatologie, Hôpital Nord Franche, 90400 Belfort, France.
Sergio CrimaldiDepartment of Orthopedic Surgery, Humanitas Research Hospital, 20089 Milan, Italy.ORCID 0000-0002-8392-3745
Demirhan DiracogluDepartment of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.
Gabriel Herrero-BeaumontJoint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, 28040 Madrid, Spain.ORCID 0000-0002-3241-991X
Giovanni IolasconDepartment of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy.ORCID 0000-0002-0976-925X
Ruxandra IonescuDepartment of Internal Medicine and Rheumatology, University of Medicine & Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Jörg JeroschDepartment of Orthopedic Surgery, Johanna Etienne Hospital, 41462 Neuss, Germany.
Jorge LaínsPhysical Rehabilitation Medicine Department, Medical Rehabilitation Centre, Rovisco Pais, 3060-586 Tocha, Portugal.ORCID 0000-0002-8737-7569
Souzi MakriEUPATI Graduate and Patient Advocate, 1350-410 Brussels, Belgium.
Natalia MartusevichDepartment of Rheumatology, Belorussian State Medical University, 220116 Minsk, Belarus.
Marco Matucci CerinicDepartment of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy.
Karel PavelkaInstitute of Rheumatology, 12800 Prague, Czech Republic.
Robert J PetrellaDepartment of Family Practice and Division of Sport and Exercise Medicine, University of British Columbia, Vancouver, BC V6Z 3B7, Canada.
Umberto TarantinoDepartment of Orthopaedics and Traumatology, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-0330-2189
Raveendhara R BannuruCenter for Treatment Comparison and Integrative Analysis, Tufts University School of Medicine, Boston, MA 02116, USA.
Fatebenefratelli Hospital · ITAssociation of Rheumatologists of Russia · RUBelarusian State Medical University · BYCarol Davila University of Medicine and Pharmacy · ROHôpital Nord · FRHospital Universitario Fundación Jiménez Díaz · ESInstitute of Rheumatology · CZIRCCS Humanitas Research Hospital · ITIstanbul University · TRJohanna-Etienne-Krankenhaus · DEPoliclinico Tor Vergata · ITSorbonne Université · FRTufts University · USUniversidade Estadual de Campinas (UNICAMP) · BRUniversité Paris-Est Créteil · FRUniversity of British Columbia · CAUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Coimbra · PTUniversity of Florence · IT

Funding

Abiogen Pharma (Italy)
6 · The paper itself

Abstract

backgroundIntra-articular hyaluronic acid (IAHA) products are often used in the treatment of adults with mild-to-moderate knee osteoarthritis (KOA). The International Symposium on Intra-Articular Treatment (ISIAT) convened a multidisciplinary technical expert panel to define characteristics for an innovative IAHA product that should answer unmet needs in the clinical management of adults with mild-to-moderate KOA.

methodsAn initial set of evidence-based statements was developed based on data extracted from articles identified through a comprehensive literature search. A Delphi panel comprising 19 experts in KOA voted in 3 rounds to rate their degree of agreement with accepted statements.

resultsThe final set of 13 accepted statements focus on the effect of an innovative IAHA across 5 key domains of nociceptive pain, joint function, quality of life, joint structure and integrity, and adverse effects. The statements set thresholds for clinically meaningful improvements that exceed those generally achievable by currently available IAHA products.

conclusionThe characteristics described by these statements from the ISIAT set new standards for what should be expected from an innovative IAHA. These statements should serve as a framework for driving the development of innovative IAHA products that will surpass the actual outcomes achieved by current viscosupplements in patients with mild-to-moderate KOA.

Indexed as

consensusinnovativeintra-articular hyaluronic acidknee osteoarthritis

Identifiers

PMID38068476
PMCPMC10707195
OpenAlexW4389182087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.